BenzingaSeptember 9, 2026 at 3:48 AM NYLast Month
Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2
Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
